ArticleFrontiers in oncology2021
MRI-Based Radiomics to Differentiate between Benign and Malignant Parotid Tumors With External Validation.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Machine learning-based radiomics for histological classification of parotid tumors using morphological MRI: a comparative study.European radiology · 2022Trial
- Editorial: Based models and machine learning on CT, MRI and PET-CT in head and neck cancer diagnosis, staging and outcome prediction.Frontiers in radiology · 2026Article
- Review
- Differentiation Between Parotid Adenolymphoma and Malignant Tumor Based on Multimodal Functional MRI of Radiomics and Intratumoral Vascular ITSS Classification.Annals of surgical oncology · 2025Article
- Classification of Parotid Tumors with Robust Radiomic Features from DCE- and DW-MRI.Journal of imaging · 2025Article
- Distinguishing atypical parotid carcinomas and pleomorphic adenomas based on multiphasic computed tomography radiomics nomogram: a multicenter study.Frontiers in oncology · 2025Article
- Clinical value of intratumoral and peritumoral CT radiomics models for discriminating benign and malignant parotid gland tumors.Frontiers in oncology · 2025Article
- Article
- Radiomic and Clinical Model in the Prognostic Evaluation of Adenoid Cystic Carcinoma of the Head and Neck.Cancers · 2024Article
- The value of T1- and FST2-Weighted-based radiomics nomogram in differentiating pleomorphic adenoma and Warthin tumor.Translational oncology · 2024Article
- The value of diffusion kurtosis imaging and dynamic contrast-enhanced magnetic resonance imaging in the differential diagnosis of parotid gland tumors.Gland surgery · 2024Article
- Deep learning-assisted diagnosis of benign and malignant parotid tumors based on ultrasound: a retrospective study.BMC cancer · 2024Article
- Different MRI-based radiomics models for differentiating misdiagnosed or ambiguous pleomorphic adenoma and Warthin tumor of the parotid gland: a multicenter study.Frontiers in oncology · 2024Article
- Performance of radiomics in the differential diagnosis of parotid tumors: a systematic review.Frontiers in oncology · 2024Review
- Preoperative CT-based intra- and peri-tumoral radiomic models for differentiating benign and malignant tumors of the parotid gland: a two-center study.American journal of cancer research · 2024Article
- Radiomics Analysis in Characterization of Salivary Gland Tumors on MRI: A Systematic Review.Cancers · 2023Review
- The Role of an MRI-Based Radiomic Signature in Predicting Malignancy of Parotid Gland Tumors.Cancers · 2023Article
- Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling.Military Medical Research · 2023Review
- A preliminary diagnostic accuracy study of quantitative MRI biomarkers for differentiating parotid tumor types.Gland surgery · 2023Article
- The Value of Multiparametric Magnetic Resonance Imaging in the Preoperative Differential Diagnosis of Parotid Gland Tumors.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe differentiation between benign and malignant parotid lesions is crucial to defining the treatment plan, which highly depends on the tumor histology. We aimed to evaluate the role of MRI-based radiomics using both T2-weighted (T2-w) images and Apparent Diffusion Coefficient (ADC) maps in the differentiation of parotid lesions, in order to develop predictive models with an external validation cohort. MATERIALS AND
methodsA sample of 69 untreated parotid lesions was evaluated retrospectively, including 37 benign (of which 13 were Warthin's tumors) and 32 malignant tumors. The patient population was divided into three groups: benign lesions (24 cases), Warthin's lesions (13 cases), and malignant lesions (32 cases), which were compared in pairs. First- and second-order features were derived for each lesion. Margins and contrast enhancement patterns (CE) were qualitatively assessed. The model with the final feature set was achieved using the support vector machine binary classification algorithm.
resultsModels for discriminating between Warthin's and malignant tumors, benign and Warthin's tumors and benign and malignant tumors had an accuracy of 86.7%, 91.9% and 80.4%, respectively. After the feature selection process, four parameters for each model were used, including histogram-based features from ADC and T2-w images, shape-based features and types of margins and/or CE. Comparable accuracies were obtained after validation with the external cohort.
conclusionsRadiomic analysis of ADC, T2-w images, and qualitative scores evaluating margins and CE allowed us to obtain good to excellent diagnostic accuracies in differentiating parotid lesions, which were confirmed with an external validation cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.